Menu
Search
|

Menu

Close
X

Flexion Therapeutics Inc FLXN.OQ (NASDAQ Stock Exchange Global Market)

24.98 USD
+1.40 (+5.94%)
As of 5:07 PM GMT
chart
Previous Close 23.58
Open 23.60
Volume 128,782
3m Avg Volume 369,862
Today’s High 25.33
Today’s Low 23.60
52 Week High 32.22
52 Week Low 16.51
Shares Outstanding (mil) 31.91
Market Capitalization (mil) 954.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.44 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.729
FY16
-2.838
FY15
-2.154
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
4.70
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
79.18
16.52
LT Debt to Equity (MRQ)
vs sector
74.28
12.22
Return on Investment (TTM)
vs sector
-35.84
14.43
Return on Equity (TTM)
vs sector
-52.41
16.13

EXECUTIVE LEADERSHIP

Patrick Mahaffy
Chairman of the Board, Since 2009
Salary: --
Bonus: --
Michael Clayman
President, Chief Executive Officer, Co-Founder, Director, Since
Salary: $500,800.00
Bonus: $330,528.00
Neil Bodick
Chief Scientific Officer, Since 2017
Salary: $400,000.00
Bonus: $176,000.00
Mark Levine
Vice President, General Counsel, Since 2017
Salary: --
Bonus: --
John Magee
Vice President - Sales, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10 Mall Rd Ste 301
BURLINGTON   MA   01803-4121

Phone: +1781.3057777

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

SPONSORED STORIES